Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Edurant

EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9

HOS-213955 · Präparat HOS-155234

8  Cimetidine Not studied. Nizatidine Ranitidine (reduced absorption due to gastric pH increase) ANTACIDS Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular hydroxide, calcium are expected. caution. Antacids should only be carbonate) administered either at least 2 hours (reduced absorption due to gastric before or at least 4 hours after pH increase) rilpivirine. NARCOTIC ANALGESICS Methadone* R(-) methadone AUC ↓ 16% No dose adjustments are required 60-100 mg once daily, R(-) methadone Cmin ↓ 22% when initiating co-administration of individualised dose R(-) methadone Cmax ↓ 14% methadone with rilpivirine. However, rilpivirine AUC ↔* clinical monitoring is recommended as rilpivirine Cmin ↔* methadone maintenance therapy may rilpivirine Cmax ↔* need to be adjusted in some patients. * based on historic controls ANTIARRHYTHMICS Digoxin* digoxin AUC ↔ No dose adjustment is required. digoxin Cmin NA digoxin Cmax ↔ ANTICOAGULANTS Dabigatran etexilate Not studied. A risk for increases in The combination of rilpivirine and dabigatran plasma concentrations dabigatran etexilate should be used cannot be excluded. with caution.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) digoxin (HOS-086172) dabigatran (HOS-112096) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165) dabigatran etexilate (HOS-086233)